ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

LIPO Lipella Pharmaceuticals Inc

0,775
0,0479 (6,59%)
03 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Lipella Pharmaceuticals Inc LIPO NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,0479 6,59% 0,775 01:49:29
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,725 0,722 0,76 0,75 0,7271
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
17.4.202414:00GLOBELipella Pharmaceuticals Expands its Advisory Board to..
05.4.202414:00GLOBELipella Pharmaceuticals to Publish Abstract Detailing..
03.4.202414:00GLOBELipella Pharmaceuticals Announces FDA Type C Meeting for..
07.3.202421:23GLOBEPRISM MarketView Spotlights Lipella Pharmaceuticals as it..
06.3.202423:05EDGAR2Form SC 13D/A - General statement of acquisition of..
06.3.202423:03EDGAR2Form SC 13D/A - General statement of acquisition of..
05.3.202414:00GLOBELipella Pharmaceuticals Announces FDA Clearance of IND for..
27.2.202423:04EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
27.2.202422:51EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
20.2.202414:00GLOBELipella Pharmaceuticals to Present at PropThink Digital..
09.2.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
07.2.202423:29EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01.2.202422:09EDGAR2Form S-3 - Registration statement under Securities Act of..
25.1.202422:06EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
03.1.202422:59EDGAR2Form SC 13G - Statement of acquisition of beneficial..
20.12.202314:00GLOBELipella Pharmaceuticals Marks Successful First Year with..
28.11.202323:28EDGAR2Form 8-K - Current report
22.11.202322:05EDGAR2Form 8-K - Current report
14.11.202312:22EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14.11.202312:14EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10.11.202314:00PRNUSFDA Grants Orphan Designation for Lipella's LP-310 Drug..
09.11.202322:07EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
01.11.202321:06EDGAR2Form S-1 - General form for registration of securities under..
25.10.202322:05PRNUSLipella Pharmaceuticals Announces Closing of $2 Million..
24.10.202314:00PRNUSLipella Pharmaceuticals Announces $2 Million Private..
20.10.202314:00PRNUSLipella Pharmaceuticals Announces FDA Clearance of IND for..
10.10.202322:05EDGAR2Form DEF 14A - Other definitive proxy statements
21.9.202314:30PRNUSLipella Pharmaceuticals' Phase 2a Clinical Study Results..
11.9.202313:38EDGAR2Form 8-K - Current report
14.8.202322:16EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14.8.202322:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.8.202322:30EDGAR2Form 8-K - Current report
02.8.202322:05EDGAR2Form 8-K - Current report
15.5.202315:17PRNUSLipella Pharmaceuticals Reports First Quarter 2023 Financial..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock